Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Hantavirus pulmonary syndrome in Canada: An overview of clinical features, diagnostics, epidemiology and prevention.

Drebot MA, Jones S, Grolla A, Safronetz D, Strong JE, Kobinger G, Lindsay RL.

Can Commun Dis Rep. 2015 Jun 4;41(6):124-131. eCollection 2015 Jun 4.

2.

The Crux of Ebola Diagnostics.

Strong JE, Feldmann H.

J Infect Dis. 2017 Dec 12;216(11):1340-1342. doi: 10.1093/infdis/jix490. No abstract available.

PMID:
29029148
3.

Delivering Prolonged Intensive Care to a Non-human Primate: A High Fidelity Animal Model of Critical Illness.

Poliquin PG, Biondi M, Ranadheera C, Hagan M, Bello A, Racine T, Allan M, Funk D, Hansen G, Hancock BJ, Kesselman M, Mortimer T, Kumar A, Jones S, Leung A, Grolla A, Tran KN, Tierney K, Qiu X, Kobasa D, Strong JE.

Sci Rep. 2017 Apr 26;7(1):1204. doi: 10.1038/s41598-017-01107-6.

4.

Reply to Colebunders.

Rosenke K, Adjemian J, Munster VJ, Strong JE, Sprecher A, Feldmann H, de Wit E.

Clin Infect Dis. 2017 Jan 15;64(2):232. doi: 10.1093/cid/ciw734. Epub 2016 Nov 9. No abstract available.

PMID:
27986680
5.

Plasmodium Parasitemia Associated With Increased Survival in Ebola Virus-Infected Patients.

Rosenke K, Adjemian J, Munster VJ, Marzi A, Falzarano D, Onyango CO, Ochieng M, Juma B, Fischer RJ, Prescott JB, Safronetz D, Omballa V, Owuor C, Hoenen T, Groseth A, Martellaro C, van Doremalen N, Zemtsova G, Self J, Bushmaker T, McNally K, Rowe T, Emery SL, Feldmann F, Williamson BN, Best SM, Nyenswah TG, Grolla A, Strong JE, Kobinger G, Bolay FK, Zoon KC, Stassijns J, Giuliani R, de Smet M, Nichol ST, Fields B, Sprecher A, Massaquoi M, Feldmann H, de Wit E.

Clin Infect Dis. 2016 Oct 15;63(8):1026-33. doi: 10.1093/cid/ciw452. Epub 2016 Aug 15.

6.

Environmental Contamination and Persistence of Ebola Virus RNA in an Ebola Treatment Center.

Poliquin PG, Vogt F, Kasztura M, Leung A, Deschambault Y, Van den Bergh R, Dorion C, Maes P, Kamara A, Kobinger G, Sprecher A, Strong JE.

J Infect Dis. 2016 Oct 15;214(suppl 3):S145-S152. Epub 2016 Jun 30.

PMID:
27365495
7.

Ebola Laboratory Response at the Eternal Love Winning Africa Campus, Monrovia, Liberia, 2014-2015.

de Wit E, Rosenke K, Fischer RJ, Marzi A, Prescott J, Bushmaker T, van Doremalen N, Emery SL, Falzarano D, Feldmann F, Groseth A, Hoenen T, Juma B, McNally KL, Ochieng M, Omballa V, Onyango CO, Owuor C, Rowe T, Safronetz D, Self J, Williamson BN, Zemtsova G, Grolla A, Kobinger G, Rayfield M, Ströher U, Strong JE, Best SM, Ebihara H, Zoon KC, Nichol ST, Nyenswah TG, Bolay FK, Massaquoi M, Feldmann H, Fields B.

J Infect Dis. 2016 Oct 15;214(suppl 3):S169-S176. Epub 2016 Jun 21.

8.

The Merits of Malaria Diagnostics during an Ebola Virus Disease Outbreak.

de Wit E, Falzarano D, Onyango C, Rosenke K, Marzi A, Ochieng M, Juma B, Fischer RJ, Prescott JB, Safronetz D, Omballa V, Owuor C, Hoenen T, Groseth A, van Doremalen N, Zemtsova G, Self J, Bushmaker T, McNally K, Rowe T, Emery SL, Feldmann F, Williamson B, Nyenswah TG, Grolla A, Strong JE, Kobinger G, Stroeher U, Rayfield M, Bolay FK, Zoon KC, Stassijns J, Tampellini L, de Smet M, Nichol ST, Fields B, Sprecher A, Feldmann H, Massaquoi M, Munster VJ.

Emerg Infect Dis. 2016 Feb;22(2):323-6. doi: 10.3201/eid2202.151656.

9.

Ebola viral load at diagnosis associates with patient outcome and outbreak evolution.

de La Vega MA, Caleo G, Audet J, Qiu X, Kozak RA, Brooks JI, Kern S, Wolz A, Sprecher A, Greig J, Lokuge K, Kargbo DK, Kargbo B, Di Caro A, Grolla A, Kobasa D, Strong JE, Ippolito G, Van Herp M, Kobinger GP.

J Clin Invest. 2015 Dec;125(12):4421-8. doi: 10.1172/JCI83162. Epub 2015 Nov 9.

10.

EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain.

Marzi A, Robertson SJ, Haddock E, Feldmann F, Hanley PW, Scott DP, Strong JE, Kobinger G, Best SM, Feldmann H.

Science. 2015 Aug 14;349(6249):739-42. doi: 10.1126/science.aab3920. Epub 2015 Aug 6.

11.

Correction for Osterholm et al., Transmission of Ebola Viruses: What We Know and What We Do Not Know.

Osterholm MT, Moore KA, Kelley NS, Brosseau LM, Wong G, Murphy FA, Peters CJ, LeDuc JW, Russell PK, Van Herp M, Kapetshi J, Muyembe JJ, Ilunga BK, Strong JE, Grolla A, Wolz A, Kargbo B, Kargbo DK, Sanders DA, Kobinger GP.

MBio. 2015 Jul 21;6(4):e01154. doi: 10.1128/mBio.01154-15. No abstract available.

12.

Considerations in the Use of Nonhuman Primate Models of Ebola Virus and Marburg Virus Infection.

Geisbert TW, Strong JE, Feldmann H.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S91-7. doi: 10.1093/infdis/jiv284. Epub 2015 Jun 10.

13.

Evaluating environmental persistence and disinfection of the Ebola virus Makona variant.

Cook BW, Cutts TA, Nikiforuk AM, Poliquin PG, Court DA, Strong JE, Theriault SS.

Viruses. 2015 Apr 14;7(4):1975-86. doi: 10.3390/v7041975.

14.

Transmission of Ebola viruses: what we know and what we do not know.

Osterholm MT, Moore KA, Kelley NS, Brosseau LM, Wong G, Murphy FA, Peters CJ, LeDuc JW, Russell PK, Van Herp M, Kapetshi J, Muyembe JJ, Ilunga BK, Strong JE, Grolla A, Wolz A, Kargbo B, Kargbo DK, Sanders DA, Kobinger GP.

MBio. 2015 Feb 19;6(2):e00137. doi: 10.1128/mBio.00137-15. Review. Erratum in: MBio. 2015;6(4):e01154. Formenty, Pierre [Deleted].

15.

Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.

Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, Fausther-Bovendo H, Wei H, Aviles J, Hiatt E, Johnson A, Morton J, Swope K, Bohorov O, Bohorova N, Goodman C, Kim D, Pauly MH, Velasco J, Pettitt J, Olinger GG, Whaley K, Xu B, Strong JE, Zeitlin L, Kobinger GP.

Nature. 2014 Oct 2;514(7520):47-53. doi: 10.1038/nature13777. Epub 2014 Aug 29.

16.

Effect of two jumping programs on hip bone mineral density in premenopausal women: a randomized controlled trial.

Tucker LA, Strong JE, LeCheminant JD, Bailey BW.

Am J Health Promot. 2015 Jan-Feb;29(3):158-64. doi: 10.4278/ajhp.130430-QUAN-200.

PMID:
24460005
17.

Flexibility of mobile laboratory unit in support of patient management during the 2007 Ebola-Zaire outbreak in the Democratic Republic of Congo.

Grolla A, Jones S, Kobinger G, Sprecher A, Girard G, Yao M, Roth C, Artsob H, Feldmann H, Strong JE.

Zoonoses Public Health. 2012 Sep;59 Suppl 2:151-7. doi: 10.1111/j.1863-2378.2012.01477.x.

PMID:
22958259
18.

A recently isolated Lassa virus from Mali demonstrates atypical clinical disease manifestations and decreased virulence in cynomolgus macaques.

Safronetz D, Strong JE, Feldmann F, Haddock E, Sogoba N, Brining D, Geisbert TW, Scott DP, Feldmann H.

J Infect Dis. 2013 Apr 15;207(8):1316-27. doi: 10.1093/infdis/jit004. Epub 2013 Jan 9.

19.

Recently emerged swine influenza A virus (H2N3) causes severe pneumonia in Cynomolgus macaques.

Richt JA, Rockx B, Ma W, Feldmann F, Safronetz D, Marzi A, Kobasa D, Strong JE, Kercher L, Long D, Gardner D, Brining D, Feldmann H.

PLoS One. 2012;7(7):e39990. doi: 10.1371/journal.pone.0039990. Epub 2012 Jul 11.

20.

Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies.

Qiu X, Audet J, Wong G, Pillet S, Bello A, Cabral T, Strong JE, Plummer F, Corbett CR, Alimonti JB, Kobinger GP.

Sci Transl Med. 2012 Jun 13;4(138):138ra81. doi: 10.1126/scitranslmed.3003876.

21.

Risk factors for late postpartum preeclampsia.

Larsen WI, Strong JE, Farley JH.

J Reprod Med. 2012 Jan-Feb;57(1-2):35-8.

PMID:
22324265
22.

Evaluation of Different Strategies for Post-Exposure Treatment of Ebola Virus Infection in Rodents.

Richardson JS, Wong G, Pillet S, Schindle S, Ennis J, Turner J, Strong JE, Kobinger GP.

J Bioterror Biodef. 2011 Oct 20;(S1). pii: 007.

23.

Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus.

Falzarano D, Feldmann F, Grolla A, Leung A, Ebihara H, Strong JE, Marzi A, Takada A, Jones S, Gren J, Geisbert J, Jones SM, Geisbert TW, Feldmann H.

J Infect Dis. 2011 Nov;204 Suppl 3:S1082-9. doi: 10.1093/infdis/jir350.

24.

The use of a mobile laboratory unit in support of patient management and epidemiological surveillance during the 2005 Marburg Outbreak in Angola.

Grolla A, Jones SM, Fernando L, Strong JE, Ströher U, Möller P, Paweska JT, Burt F, Pablo Palma P, Sprecher A, Formenty P, Roth C, Feldmann H.

PLoS Negl Trop Dis. 2011 May;5(5):e1183. doi: 10.1371/journal.pntd.0001183. Epub 2011 May 24.

25.

Factors associated with Marburg hemorrhagic fever: analysis of patient data from Uige, Angola.

Roddy P, Thomas SL, Jeffs B, Nascimento Folo P, Pablo Palma P, Moco Henrique B, Villa L, Damiao Machado FP, Bernal O, Jones SM, Strong JE, Feldmann H, Borchert M.

J Infect Dis. 2010 Jun 15;201(12):1909-18. doi: 10.1086/652748.

26.

Lethal influenza virus infection in macaques is associated with early dysregulation of inflammatory related genes.

Cillóniz C, Shinya K, Peng X, Korth MJ, Proll SC, Aicher LD, Carter VS, Chang JH, Kobasa D, Feldmann F, Strong JE, Feldmann H, Kawaoka Y, Katze MG.

PLoS Pathog. 2009 Oct;5(10):e1000604. doi: 10.1371/journal.ppat.1000604. Epub 2009 Oct 2.

27.

Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine.

Richardson JS, Yao MK, Tran KN, Croyle MA, Strong JE, Feldmann H, Kobinger GP.

PLoS One. 2009;4(4):e5308. doi: 10.1371/journal.pone.0005308. Epub 2009 Apr 23.

28.

Disease modeling for Ebola and Marburg viruses.

Bente D, Gren J, Strong JE, Feldmann H.

Dis Model Mech. 2009 Jan-Feb;2(1-2):12-7. doi: 10.1242/dmm.000471.

29.

Stimulation of Ebola virus production from persistent infection through activation of the Ras/MAPK pathway.

Strong JE, Wong G, Jones SE, Grolla A, Theriault S, Kobinger GP, Feldmann H.

Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17982-7. doi: 10.1073/pnas.0809698105. Epub 2008 Nov 3.

30.

Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice.

Croyle MA, Patel A, Tran KN, Gray M, Zhang Y, Strong JE, Feldmann H, Kobinger GP.

PLoS One. 2008;3(10):e3548. doi: 10.1371/journal.pone.0003548. Epub 2008 Oct 29.

31.

The ecology of Ebola virus.

Groseth A, Feldmann H, Strong JE.

Trends Microbiol. 2007 Sep;15(9):408-16. Epub 2007 Aug 15. Review.

PMID:
17698361
32.

Panmicrobial oligonucleotide array for diagnosis of infectious diseases.

Palacios G, Quan PL, Jabado OJ, Conlan S, Hirschberg DL, Liu Y, Zhai J, Renwick N, Hui J, Hegyi H, Grolla A, Strong JE, Towner JS, Geisbert TW, Jahrling PB, Büchen-Osmond C, Ellerbrok H, Sanchez-Seco MP, Lussier Y, Formenty P, Nichol MS, Feldmann H, Briese T, Lipkin WI.

Emerg Infect Dis. 2007 Jan;13(1):73-81.

33.

Laboratory diagnosis of Ebola and Marburg hemorrhagic fever.

Grolla A, Lucht A, Dick D, Strong JE, Feldmann H.

Bull Soc Pathol Exot. 2005 Sep;98(3):205-9. Review.

PMID:
16267962
34.

Severe acute respiratory syndrome-related coronavirus is inhibited by interferon- alpha.

Ströher U, DiCaro A, Li Y, Strong JE, Aoki F, Plummer F, Jones SM, Feldmann H.

J Infect Dis. 2004 Apr 1;189(7):1164-7. Epub 2004 Mar 12.

PMID:
15031783
36.

Reovirus oncolysis of human breast cancer.

Norman KL, Coffey MC, Hirasawa K, Demetrick DJ, Nishikawa SG, DiFrancesco LM, Strong JE, Lee PW.

Hum Gene Ther. 2002 Mar 20;13(5):641-52.

PMID:
11916487
37.

Reovirus therapy of tumors with activated Ras pathway.

Coffey MC, Strong JE, Forsyth PA, Lee PW.

Science. 1998 Nov 13;282(5392):1332-4.

38.

Validity of the Perceived Criticism Measure in an undergraduate sample.

White JD, Strong JE, Chambless DL.

Psychol Rep. 1998 Aug;83(1):83-97.

PMID:
9775664
39.

The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus.

Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW.

EMBO J. 1998 Jun 15;17(12):3351-62.

40.
41.

Recognition of the epidermal growth factor receptor by reovirus.

Tang D, Strong JE, Lee PW.

Virology. 1993 Nov;197(1):412-4.

PMID:
8212575
42.
43.
44.

Conformational and functional analysis of the C-terminal globular head of the reovirus cell attachment protein.

Duncan R, Horne D, Strong JE, Leone G, Pon RT, Yeung MC, Lee PW.

Virology. 1991 Jun;182(2):810-9.

PMID:
2024499
45.

The safety and efficacy of intrathecal diamorphine.

Barron DW, Strong JE.

Pain. 1984 Mar;18(3):279-85.

PMID:
6203085
46.

Bleomycin clinical pharmacology by radioimmunoassay.

Hall SW, Strong JE, Broughton A, Frazier ML, Benjamin RS.

Cancer Chemother Pharmacol. 1982;9(1):22-5.

PMID:
6183016
47.
48.

Pharmacokinetics of bleomycin after im administration in man.

Oken MM, Crooke ST, Elson MK, Strong JE, Shafer RB.

Cancer Treat Rep. 1981 May-Jun;65(5-6):485-9.

PMID:
6165473
49.

Preliminary studies of the pharmacokinetics of talisomycin in the rhesus monkey.

Van Harken DR, Smyth RD, Lee FH, Strong JE, Hottendorf GH.

Res Commun Chem Pathol Pharmacol. 1981 Mar;31(3):403-17.

PMID:
6166971
50.

Tallysomycin, a third generation bleomycin analog.

Crooke ST, Strong JE, Bradner WT, Schurig J, Schlein A, Prestayko AW.

Recent Results Cancer Res. 1981;76:83-90. No abstract available.

PMID:
6165058

Supplemental Content

Loading ...
Support Center